Member Directory - Viral Hepatitis Working Group

Chair: David Thomas

Objectives:

  • Promote development of long-acting approaches to the treatment and/or prevention of hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. With HCV infection, the ultimate goal is a ‘test and cure’ approach to elimination.  With HBV infection, long-acting formulations to simplify treatment and prevention.
  • Bring clinical, public health, and regulatory expertise to solve this pharmacological challenge by identifying the optimal drug targets and encouraging their development in partnership with Pharma.  
  • Prioritize existing compounds with the pharmacologic and chemical properties that support long-acting formulation.

Interested in joining?

Please submit your request and your CV to Ana Cervantes. Acceptance requires a written nomination from a Hepatitis Working Group member and majority approval.

David Thomas is Director of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine. His research is focused on hepatitis viruses, especially interactions between HIV and viral hepatitis. Dr. Thomas has served the National Institutes of Health and leading professional societies and the associated biomedical journals in multiple leadership/editorial capacities.

Dr. Bollinger is Founding Director of the Center for Clinical Global Health Education (CCGHE) and Professor of Infectious Diseases at the Johns Hopkins University (JHU) School of Medicine. He holds joint appointments in international health at the Johns Hopkins (JH) Bloomberg School of Public Health, and in community public health at the JH School of Nursing.

Daniel E Cohen, MD, is a Group Medical Director in Clinical Development at AbbVie, where his areas of responsibility include viral diseases and cystic fibrosis. Dr. Cohen has extensive experience in clinical drug development for HIV and hepatitis C, and has been involved in the approval of Viekira Pak, Technivie, and Mavyret. 

Dr. Feld attended medical school at the University of Toronto and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis. 

Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP). He is Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and Professor of Pharmacology and Molecular Sciences in the Johns Hopkins University School of Medicine. He is also Professor of International Health in the Johns Hopkins University Bloomberg School of Public Health.

Leah Johnson, PhD, is a Senior Research Chemist in the Center for Engineered Systems at RTI International. Dr. Johnson’s research interests include the design and development of polymer-based biosensors and drug delivery systems and translation to early stage products. She currently leads a research group focused on the development long-acting biodegradable implants for prevention and treatment of HIV and as a multipurpose prevention technology

Mila Maistat works as Policy and Advocacy Manager with the Medicines Patent Pool (MPP). She has almost 20 years of experience of working in public health, in particular, viral hepatitis and HIV policy, advocacy and access to medicines. Mila has been serving with WHO as a member of WHO STAC on viral hepatitis and the WHO guidelines’ development and peer-review groups, development of regional and country plans on HIV, viral hepatitis and TB, used to chair HepC Group for the UNITAID NGO delegation, member of HIV, viral hepatitis and TB in Europe Steering Committee, part of organizing and scientific committees for international conferences and meetings on viral hepatitis and HIV.

Craig McClure leads the Viral Hepatitis Program at the Clinton Health Access Initiative (CHAI). In this capacity, he directs a global team supporting seven countries in Africa and Asia to scale up diagnosis and treatment of viral hepatitis, with an emphasis on hepatitis C, including market-shaping interventions to introduce innovations in diagnostics and drugs, increase volumes and drive down pricing, support for policy and program development, financing, training of health workers, and monitoring and evaluation.

Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases Johns Hopkins Bayview Medical Center. He also serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine and is the Associate Dean for Research in the Capital Region (CAPRES).